Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Barry Maron and Ethan Rowin.
Barry Maron
Connection Strength
31.213
Ethan Rowin
  1. Maron BJ, Casey S, Sengupta JD, Sharkey SW, Maron MS, Rowin EJ. Experience With Extended Follow-Up of?Prophylactically Implanted Defibrillators?for High-Risk Patients With?Hypertrophic?Cardiomyopathy. JACC Adv. 2024 Nov; 3(11):101317.
    View in: PubMed
    Score: 0.972
  2. Maron BJ, Maron MS, Rowin EJ. Precision Medicine for All?: What About Hypertrophic Cardiomyopathy? JACC Adv. 2024 May; 3(5):100922.
    View in: PubMed
    Score: 0.938
  3. Rowin EJ, Wadid M, Maron MS, White M, Hook BG, Harnish P, Silver JS, Reynolds MR, Maron BJ. Assessing the impact of atrial fibrillation on symptoms and quality of life in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2024 Apr; 35(4):654-663.
    View in: PubMed
    Score: 0.926
  4. Rowin EJ, Link MS, Maron MS, Maron BJ. Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2023 11 28; 148(22):1797-1811.
    View in: PubMed
    Score: 0.915
  5. Maron BJ, Maron MS, Sherrid MV, Ommen SR, Rowin EJ. Personalized Treatment Strategies Effective in Hypertrophic Cardiomyopathy Do Not Rely on Genomics in 2022: A Different Tale of Precision Medicine. Am J Cardiol. 2022 11 15; 183:150-152.
    View in: PubMed
    Score: 0.842
  6. Maron BJ, Maron MS, Sherrid MV, Rowin EJ. Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2022 05 03; 11(9):e024566.
    View in: PubMed
    Score: 0.821
  7. Rowin EJ, Maron MS, Adler A, Albano AJ, Varnava AM, Spears D, Marsy D, Heitner SB, Cohen E, Leong KMW, Winters SL, Martinez MW, Koethe BC, Rakowski H, Maron BJ. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study. Heart Rhythm. 2022 05; 19(5):782-789.
    View in: PubMed
    Score: 0.800
  8. Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008123.
    View in: PubMed
    Score: 0.732
  9. Rowin EJ, Sridharan A, Madias C, Firely C, Koethe B, Link MS, Maron MS, Maron BJ. Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 08 01; 128:75-83.
    View in: PubMed
    Score: 0.716
  10. Rowin EJ, Maron MS, Bhatt V, Gillam L, Maron BJ. Hypertrophic Cardiomyopathy in "Real-World" Community Cardiology Practice. Am J Cardiol. 2020 05 01; 125(9):1398-1403.
    View in: PubMed
    Score: 0.703
  11. Rowin EJ, Maron MS, Wells S, Patel PP, Koethe BC, Maron BJ. Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2019 11 05; 8(21):e012041.
    View in: PubMed
    Score: 0.690
  12. Rowin EJ, Maron MS, Maron BJ. Response by Rowin et al to Letter Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy". Circulation. 2018 06 05; 137(23):2541-2542.
    View in: PubMed
    Score: 0.626
  13. Rowin EJ, Maron MS, Chan RH, Hausvater A, Wang W, Rastegar H, Maron BJ. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017 Dec 15; 120(12):2256-2264.
    View in: PubMed
    Score: 0.596
  14. Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017 Dec 19; 136(25):2420-2436.
    View in: PubMed
    Score: 0.595
  15. Maron BJ, Maron MS, Rowin EJ. Perspectives on the Overall Risks of Living With Hypertrophic Cardiomyopathy. Circulation. 2017 06 13; 135(24):2317-2319.
    View in: PubMed
    Score: 0.585
  16. Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, Maron BJ. Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017 06 01; 119(11):1862-1865.
    View in: PubMed
    Score: 0.575
  17. Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012 Jan; 5(1):119-22.
    View in: PubMed
    Score: 0.401
  18. Fath AR, Aglan A, Maron MS, Phillips JS, Maron BJ, Rowin EJ. Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy. Int J Cardiol. 2025 Feb 19; 426:133082.
    View in: PubMed
    Score: 0.249
  19. Massera D, Sherrid MV, Adlestein E, Bokhari N, Alvarez IC, Wu WY, Reuter MC, Maron MS, Maron BJ, Rowin EJ. Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5?Years. J Am Heart Assoc. 2025 Jan 21; 14(2):e037639.
    View in: PubMed
    Score: 0.247
  20. Rowin EJ, Das G, Madias C, Hsu M, Crosson L, Turakhia MP, Maron BJ, Maron MS. Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy. Heart Rhythm. 2024 Sep 20.
    View in: PubMed
    Score: 0.242
  21. Maron MS, Rowin EJ, Maron BJ. Letter by Maron et al Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes". Circulation. 2024 Sep 17; 150(12):e255-e256.
    View in: PubMed
    Score: 0.242
  22. Aglan A, Fath AR, Maron BJ, Maron MS, Prasad A, Almomani A, Hammadah M, Reynolds MR, Rowin EJ. Percutaneous left atrial appendage closure for stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation. Heart Rhythm. 2024 09; 21(9):1677-1683.
    View in: PubMed
    Score: 0.237
  23. Abraham S, Rowin EJ, Saji AM, Silver JS, Shekar PS, Maron MS, Maron BJ. Significance and Frequency of Incidental Fortuitous Clinical Identifications of Hypertrophic Cardiomyopathy. JACC Adv. 2024 Jun; 3(6):100948.
    View in: PubMed
    Score: 0.235
  24. Aglan A, Fath AR, Eldaly AS, Anderson AS, Phillips JS, Maron BJ, Maron MS, Rowin EJ. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Mortality in Hypertrophic Cardiomyopathy. JACC Adv. 2024 Mar; 3(3):100843.
    View in: PubMed
    Score: 0.232
  25. Maron MS, Rowin EJ, Maron BJ. The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Am J Cardiol. 2024 02 01; 212S:S64-S76.
    View in: PubMed
    Score: 0.231
  26. Maron BJ, Rowin EJ, Maron MS. Advances in the Management of Hypertrophic Cardiomyopathy Leading to Low Disease-Related Mortality in 2023. Am J Cardiol. 2024 02 01; 212S:S77-S82.
    View in: PubMed
    Score: 0.231
  27. Carrick RT, Ahamed H, Sung E, Maron MS, Madias C, Avula V, Studley R, Bao C, Bokhari N, Quintana E, Rajesh-Kannan R, Maron BJ, Wu KC, Rowin EJ. Identification of high-risk imaging features in hypertrophic cardiomyopathy using electrocardiography: A deep-learning approach. Heart Rhythm. 2024 08; 21(8):1390-1397.
    View in: PubMed
    Score: 0.231
  28. Maron BJ, Rowin EJ, Maron MS. Commotio cordis?once again: Unusual occurrence in a noncontact sport. HeartRhythm Case Rep. 2023 Dec; 9(12):855-857.
    View in: PubMed
    Score: 0.228
  29. Studley R, Madias C, Bokhari N, Carrick RT, Quintana E, Bao C, Maron BJ, Maron MS, Rowin EJ. QRS Fragmentation as a Risk Marker for Sudden Death in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2023 11; 9(11):2353-2355.
    View in: PubMed
    Score: 0.225
  30. Maron MS, Mitten M, Borchers J, Rowin EJ, Maron BJ. Medical and Legal Determinants of Sports Eligibility for Young Competitive Athletes With Cardiovascular Disease. J Am Coll Cardiol. 2023 08 29; 82(9):828-832.
    View in: PubMed
    Score: 0.224
  31. Maron BJ, Estes NAM, Rowin EJ, Maron MS, Reynolds MR. Development of the Implantable Cardioverter-Defibrillator: JACC Historical Breakthroughs in Perspective. J Am Coll Cardiol. 2023 07 25; 82(4):353-373.
    View in: PubMed
    Score: 0.223
  32. Maron MS, Rowin EJ, Bonaventura J, Maron BJ. Do Implantable Cardioverter-Defibrillators Really Belong on the Athlete Field? Am J Cardiol. 2023 08 01; 200:236-238.
    View in: PubMed
    Score: 0.222
  33. Bonaventura J, Rowin EJ, Maron MS, Maron BJ. Is Hypertrophic Cardiomyopathy Always a Familial and Inherited Disease? J Am Heart Assoc. 2023 06 20; 12(12):e028974.
    View in: PubMed
    Score: 0.221
  34. Massera D, Sherrid MV, Maron MS, Rowin EJ, Maron BJ. How common is hypertrophic cardiomyopathy? really?: Disease prevalence revisited 27?years after CARDIA. Int J Cardiol. 2023 07 01; 382:64-67.
    View in: PubMed
    Score: 0.219
  35. Maron MS, Rowin E, Spirito P, Maron BJ. Differing strategies for sudden death prevention in hypertrophic cardiomyopathy. Heart. 2023 03 27; 109(8):589-594.
    View in: PubMed
    Score: 0.218
  36. Maron BJ, Rowin EJ, Ambe SP, Maron MS. The Reply. Am J Med. 2023 03; 136(3):e50.
    View in: PubMed
    Score: 0.217
  37. Bonaventura J, Rowin EJ, Maron MS, Maron BJ. Risks of the Athletic Field Revisited: Report of Unusual Occurrences of Cardiac Arrest and Sudden Death in Professional Soccer Players. Am J Med. 2023 03; 136(3):315-321.
    View in: PubMed
    Score: 0.214
  38. Rowin EJ, Ruberg FL, Das G, Higgins D, Lipe WC, Bokhari N, Dehn M, Maron BJ, Maron MS. Identification of Transthyretin Cardiac Amyloidosis Among Patients Previously Diagnosed With Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2022 12; 15(12):e014938.
    View in: PubMed
    Score: 0.214
  39. Maron BA, Kleiner DE, Arons E, Wertheim BM, Sharma NS, Haley KJ, Samokhin AO, Rowin EJ, Maron MS, Rosing DR, Maron BJ. Evidence of Advanced Pulmonary Vascular Remodeling in Obstructive Hypertrophic Cardiomyopathy With Pulmonary Hypertension. Chest. 2023 03; 163(3):678-686.
    View in: PubMed
    Score: 0.212
  40. Maron BJ, Dearani JA, Smedira NG, Schaff HV, Wang S, Rastegar H, Ralph-Edwards A, Ferrazzi P, Swistel D, Shemin RJ, Quintana E, Bannon PG, Shekar PS, Desai M, Roberts WC, Lever HM, Adler A, Rakowski H, Spirito P, Nishimura RA, Ommen SR, Sherrid MV, Rowin EJ, Maron MS. Ventricular Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy (Analysis Spanning 60 Years Of Practice): AJC Expert Panel. Am J Cardiol. 2022 10 01; 180:124-139.
    View in: PubMed
    Score: 0.209
  41. Rowin EJ, Cooper C, Carrick RT, Tsoi M, Maron BJ, Maron MS. Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2022 09 15; 179:70-73.
    View in: PubMed
    Score: 0.208
  42. Maron MS, Lanuario EL, Rowin EJ, Maron BJ. Global Dissemination and Implementation of Contemporary Management Principles for Hypertrophic Cardiomyopathy and Role of the International HCM Summit. Am J Cardiol. 2022 06 01; 172:146-149.
    View in: PubMed
    Score: 0.206
  43. Maron BJ, Rowin EJ, Ambe SP, Maron MS. Changing Demographics in Hypertrophic Cardiomyopathy and Implications for Management: Clinical Research. Am J Med. 2022 10; 135(10):1244-1246.
    View in: PubMed
    Score: 0.206
  44. Maron MS, Rosing DR, Braunwald E, Rastegar H, Koethe B, Roberts WC, Maron BJ, Rowin EJ. Sixty-Year Evolution of Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy with Insights From the Historic NIH Surgical Experience to Present. Am J Cardiol. 2022 06 01; 172:107-108.
    View in: PubMed
    Score: 0.204
  45. Maron BJ, Rowin EJ, Madias C, Dolan N, Maron MS. Cats Have Nine Lives but This Hypertrophic Cardiomyopathy Patient Has Had Ten (So Far). Am J Cardiol. 2022 04 01; 168:163-165.
    View in: PubMed
    Score: 0.202
  46. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV. Diagnosis and Evaluation of Hypertrophic?Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 02 01; 79(4):372-389.
    View in: PubMed
    Score: 0.202
  47. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 02 01; 79(4):390-414.
    View in: PubMed
    Score: 0.202
  48. Maron BJ, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy: New Concepts and Therapies. Annu Rev Med. 2022 01 27; 73:363-375.
    View in: PubMed
    Score: 0.201
  49. Maron MS, Rowin EJ, Maron BJ. Is surgical myectomy challenged by emergence of novel drug therapy with mavacamten? Asian Cardiovasc Thorac Ann. 2022 Jan; 30(1):11-18.
    View in: PubMed
    Score: 0.201
  50. Sridharan A, Maron MS, Carrick RT, Madias CA, Huang D, Cooper C, Drummond J, Maron BJ, Rowin EJ. Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2022 01; 33(1):20-29.
    View in: PubMed
    Score: 0.200
  51. Maron MS, Rastegar H, Dolan N, Carpino P, Koethe B, Maron BJ, Rowin EJ. Outcomes Over Follow-up =10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2022 01 15; 163:91-97.
    View in: PubMed
    Score: 0.199
  52. Maron BJ, Maron MS, Maurer MS, Rowin EJ, Maron BA, Gali? N. Cardiovascular Diseases That Have Emerged From the Darkness. J Am Heart Assoc. 2021 10 19; 10(20):e021095.
    View in: PubMed
    Score: 0.197
  53. Udelson JE, Rowin EJ, Maron BJ. Return to Play for Athletes After COVID-19 Infection: The Fog Begins to Clear. JAMA Cardiol. 2021 09 01; 6(9):997-999.
    View in: PubMed
    Score: 0.196
  54. Rowin EJ, Maron BJ, Wells S, Burrows A, Firely C, Koethe B, Patel AR, Maron MS. Usefulness of Global Longitudinal Strain to Predict Heart Failure Progression in Patients With Nonobstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2021 07 15; 151:86-92.
    View in: PubMed
    Score: 0.194
  55. Carrick RT, Maron MS, Adler A, Wessler B, Hoss S, Chan RH, Sridharan A, Huang D, Cooper C, Drummond J, Rakowski H, Maron BJ, Rowin EJ. Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score. Circ Arrhythm Electrophysiol. 2021 06; 14(6):e009796.
    View in: PubMed
    Score: 0.193
  56. Maron BJ, Rowin EJ, Maron MS. Is Regression of Left Ventricular Hypertrophy Really a Good Thing for Patients With Hypertrophic Cardiomyopathy?: The Emerging Mavacamten Story. Am J Cardiol. 2021 05 15; 147:145-146.
    View in: PubMed
    Score: 0.188
  57. Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Heart Rhythm. 2021 06; 18(6):1012-1023.
    View in: PubMed
    Score: 0.188
  58. Maron BJ, Rowin EJ, Maron MS. Erratum to "Hypertrophic Cardiomyopathy: Is a 'Cure' Coming ? Or Is It Already Here?": American Journal of Medicine, 133 (2020):8:886-888. Am J Med. 2021 Mar; 134(3):412.
    View in: PubMed
    Score: 0.187
  59. Maron BJ, Rowin EJ, Maron MS. After 60 Years Hypertrophic Cardiomyopathy is Finally Recognized as a Contemporary Treatable Disease With Low Mortality and Morbidity, But is This Paradigm Under-Recognized in the Literature? Am J Cardiol. 2021 03 01; 142:136-137.
    View in: PubMed
    Score: 0.186
  60. Shirani J, Aurshiya R, Elshaikh A, Olenchock SA, Rowin EJ, Maron MS, Maron BJ. Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices. Am J Cardiol. 2021 03 01; 142:130-135.
    View in: PubMed
    Score: 0.186
  61. Maron MS, Rowin EJ, Maron BJ. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: the newest high-risk phenotype. Eur Heart J Cardiovasc Imaging. 2020 12 01; 21(12):1351-1352.
    View in: PubMed
    Score: 0.186
  62. Rowin EJ, Maron BJ, Maron MS. Reply: The LVAD in the Management of Advanced Heart?Failure Due to Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020 10 20; 76(16):1913.
    View in: PubMed
    Score: 0.182
  63. Maron MS, Steiger N, Burrows A, Madias C, Weinstock J, Link MS, Rowin EJ, Maron BJ. Evidence That Subcutaneous Implantable Cardioverter-Defibrillators Are Effective and Reliable in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2020 08; 6(8):1019-1021.
    View in: PubMed
    Score: 0.182
  64. Maron BJ, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here? Am J Med. 2020 08; 133(8):886-888.
    View in: PubMed
    Score: 0.182
  65. Maron MS, Brush J, Rowin EJ, Maron BJ. Back to the future: Predicting sudden death in hypertrophic cardiomyopathy relying on individual risk markers and physician judgment without mathematical scoring. Heart Rhythm. 2021 01; 18(1):148-150.
    View in: PubMed
    Score: 0.181
  66. Rowin EJ, Maron BJ, Carrick RT, Patel PP, Koethe B, Wells S, Maron MS. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. J Am Coll Cardiol. 2020 06 23; 75(24):3033-3043.
    View in: PubMed
    Score: 0.180
  67. Maron BJ, Mackey-Bojack S, Facile E, Duncanson E, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy and Sudden Death Initially Identified at Autopsy. Am J Cardiol. 2020 07 15; 127:139-141.
    View in: PubMed
    Score: 0.178
  68. Maron BJ, Rowin EJ, Arkun K, Rastegar H, Larson AM, Maron MS, Chin MT. Adult Monozygotic Twins With Hypertrophic Cardiomyopathy and Identical Disease Expression and Clinical Course. Am J Cardiol. 2020 07 15; 127:135-138.
    View in: PubMed
    Score: 0.178
  69. Maron BJ, Rowin EJ, Maron MS. Concerns About the HCM Risk-Kids Study. JAMA Cardiol. 2020 03 01; 5(3):362-363.
    View in: PubMed
    Score: 0.176
  70. Rowin EJ, Maron BJ, Maron MS. The Hypertrophic Cardiomyopathy Phenotype Viewed Through the Prism?of?Multimodality Imaging: Clinical and Etiologic Implications. JACC Cardiovasc Imaging. 2020 09; 13(9):2002-2016.
    View in: PubMed
    Score: 0.174
  71. Maron MS, Rowin EJ, Maron BJ. Editorial commentary: Hold your horses (and mice, rats, and cats): How relevant really are animal models of hypertrophic cardiomyopathy? Trends Cardiovasc Med. 2021 01; 31(1):32-33.
    View in: PubMed
    Score: 0.174
  72. Maron M, Rowin E, Maron BJ. Increasing evidence that risk scores underperform in predicting sudden death in hypertrophic cardiomyopathy. Heart. 2019 12; 105(24):1850-1851.
    View in: PubMed
    Score: 0.171
  73. Maron BJ, Rowin EJ, Maron MS. Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Circ Res. 2019 08 02; 125(4):370-378.
    View in: PubMed
    Score: 0.169
  74. Kimmelstiel C, Zisa DC, Kuttab JS, Wells S, Udelson JE, Wessler BS, Rastegar H, Kapur NK, Weintraub AR, Maron BJ, Maron MS, Rowin EJ. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. Circ Cardiovasc Interv. 2019 07; 12(7):e007673.
    View in: PubMed
    Score: 0.169
  75. Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, Romashko M, Link MS, Maron BJ. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. 2019 07 01; 4(7):644-657.
    View in: PubMed
    Score: 0.168
  76. Maron MS, Rowin EJ, Maron BJ. The ESC Risk Score Is Less Reliable than ACC/AHA Risk Factors in Hypertrophic Cardiomyopathy: When Sensitivity Trumps Specificity. Can J Cardiol. 2019 12; 35(12):1626-1628.
    View in: PubMed
    Score: 0.168
  77. Rowin EJ, Romashko M, Testani JM, Koethe BC, Saxena D, Udelson JE, Maron BJ, Maron MS. Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy. J Card Fail. 2019 08; 25(8):690-692.
    View in: PubMed
    Score: 0.168
  78. Rowin EJ, Maron BJ, Romashko M, Wang W, Rastegar H, Link MS, Maron MS. Impact of Effective Management Strategies on Patients With the Most Extreme Phenotypic Expression of Hypertrophic Cardiomyopathy. Am J Cardiol. 2019 07 01; 124(1):113-121.
    View in: PubMed
    Score: 0.166
  79. Maron BJ, Rowin EJ, Maron MS. Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". Circulation. 2019 03 19; 139(12):1557-1558.
    View in: PubMed
    Score: 0.165
  80. Maurizi N, Michels M, Rowin EJ, Semsarian C, Girolami F, Tomberli B, Cecchi F, Maron MS, Olivotto I, Maron BJ. Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. Circulation. 2019 02 05; 139(6):830-833.
    View in: PubMed
    Score: 0.164
  81. Rowin EJ, Mohanty S, Madias C, Maron BJ, Maron MS. Benefit of Cardiac Resynchronization Therapy in End-Stage Nonobstructive Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2019 01; 5(1):131-133.
    View in: PubMed
    Score: 0.163
  82. Maron MS, Udelson JE, Rowin EJ, Maron BJ. Reply: Atrial Fibrillation in Hypertrophic Cardiomyopathy. JACC Heart Fail. 2018 09; 6(9):807-808.
    View in: PubMed
    Score: 0.159
  83. Rowin EJ, Maron BJ, Chokshi A, Kannappan M, Arkun K, Wang W, Rastegar H, Maron MS. Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy. Am J Cardiol. 2018 10 15; 122(8):1409-1420.
    View in: PubMed
    Score: 0.158
  84. Rowin EJ, Maron BJ, Chokshi A, Maron MS. Left?ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age. Pacing Clin Electrophysiol. 2018 Jun 12.
    View in: PubMed
    Score: 0.157
  85. Wells S, Rowin EJ, Bhatt V, Maron MS, Maron BJ. Association Between Race and Clinical Profile of Patients Referred for Hypertrophic Cardiomyopathy. Circulation. 2018 05 01; 137(18):1973-1975.
    View in: PubMed
    Score: 0.155
  86. Maron BJ, Rowin EJ, Maron MS. Global Burden of Hypertrophic?Cardiomyopathy. JACC Heart Fail. 2018 05; 6(5):376-378.
    View in: PubMed
    Score: 0.155
  87. Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical Spectrum and Management?of?Heart Failure in?Hypertrophic?Cardiomyopathy. JACC Heart Fail. 2018 05; 6(5):353-363.
    View in: PubMed
    Score: 0.155
  88. Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circ Arrhythm Electrophysiol. 2018 04; 11(4):e005820.
    View in: PubMed
    Score: 0.155
  89. Wells S, Rowin EJ, Boll G, Rastegar H, Wang W, Maron MS, Maron BJ. Clinical Profile of Nonresponders to Surgical Myectomy with Obstructive Hypertrophic Cardiomyopathy. Am J Med. 2018 06; 131(6):e235-e239.
    View in: PubMed
    Score: 0.153
  90. Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, Maron MS, DeNofrio D. Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. Am J Cardiol. 2018 04 15; 121(8):986-996.
    View in: PubMed
    Score: 0.153
  91. Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of Exercise Testing in Hypertrophic?Cardiomyopathy. JACC Cardiovasc Imaging. 2017 11; 10(11):1374-1386.
    View in: PubMed
    Score: 0.150
  92. Maron MS, Xin W, Sims KB, Butler R, Haas TS, Rowin EJ, Desnick RJ, Maron BJ. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018 02; 131(2):200.e1-200.e8.
    View in: PubMed
    Score: 0.149
  93. Rowin EJ, Maron BJ, Arkun K, Maron MS. Anatomic validation of late gadolinium enhancement as evidence of myocardial scarring in LAMP2 cardiomyopathy. Eur Heart J. 2017 08 14; 38(31):2444.
    View in: PubMed
    Score: 0.148
  94. Maron BJ, Rowin EJ, Maron MS, Braunwald E. Achieving Extended Longevity and Quality of Life for Senior Patients With Hypertrophic Cardiomyopathy: What Is Possible. Am J Med. 2017 Nov; 130(11):1236-1237.
    View in: PubMed
    Score: 0.147
  95. Rowin EJ, Maron BJ, Maron MS. Reply: Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm. J Am Coll Cardiol. 2017 07 18; 70(3):407.
    View in: PubMed
    Score: 0.147
  96. Kannappan M, Maron BJ, Rastegar H, Pandian NG, Maron MS, Rowin EJ. Underappreciated occurrence of discrete subaortic membranes producing left ventricular outflow obstruction in hypertrophic cardiomyopathy. Echocardiography. 2017 Aug; 34(8):1247-1249.
    View in: PubMed
    Score: 0.147
  97. Maron MS, Rowin EJ, Maron BJ. How to Image Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2017 07; 10(7).
    View in: PubMed
    Score: 0.147
  98. Link MS, Bockstall K, Weinstock J, Alsheikh-Ali AA, Semsarian C, Estes NAM, Spirito P, Haas TS, Rowin EJ, Maron MS, Maron BJ. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications. J Cardiovasc Electrophysiol. 2017 May; 28(5):531-537.
    View in: PubMed
    Score: 0.144
  99. Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, Maron MS. Hypertrophic Cardiomyopathy With Left?Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol. 2017 02 21; 69(7):761-773.
    View in: PubMed
    Score: 0.143
  100. Maron BJ, Dearani JA, Maron MS, Ommen SR, Rastegar H, Nishimura RA, Swistel DG, Sherrid MV, Ralph-Edwards A, Rakowski H, Smedira NG, Rowin EJ, Desai MY, Lever HM, Spirito P, Ferrazzi P, Schaff HV. Why we need more septal myectomy surgeons: An emerging recognition. J Thorac Cardiovasc Surg. 2017 11; 154(5):1681-1685.
    View in: PubMed
    Score: 0.143
  101. Maron BJ, Rowin EJ, Maron MS, Braunwald E. Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored ? Until Now. Am J Med. 2017 02; 130(2):119-123.
    View in: PubMed
    Score: 0.140
  102. Maron BJ, Rowin EJ, Casey SA, Maron MS. How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice. JAMA Cardiol. 2016 04 01; 1(1):98-105.
    View in: PubMed
    Score: 0.135
  103. Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, Garberich RF, Link MS, Chan RHM, Lesser JR, Maron BJ. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2016 Mar 29; 67(12):1399-1409.
    View in: PubMed
    Score: 0.134
  104. Maron BJ, Rowin EJ, Casey SA, Garberich RF, Maron MS. What Do Patients With Hypertrophic Cardiomyopathy Die from? Am J Cardiol. 2016 Feb 01; 117(3):434-5.
    View in: PubMed
    Score: 0.131
  105. Maron BJ, Rowin EJ, Casey SA, Lesser JR, Garberich RF, McGriff DM, Maron MS. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Circulation. 2016 Jan 05; 133(1):62-73.
    View in: PubMed
    Score: 0.131
  106. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, Ralph-Edwards A, Rakowski H, Sherrid MV, Swistel DG, Balaram S, Rastegar H, Rowin EJ, Smedira NG, Lytle BW, Desai MY, Lever HM. Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction. J Am Coll Cardiol. 2015 Sep 15; 66(11):1307-1308.
    View in: PubMed
    Score: 0.130
  107. Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):757-64.
    View in: PubMed
    Score: 0.127
  108. Maron BJ, Rowin EJ, Kalra A, Lesser JR, Maron MS. Reply: To PMID 25759101. Am J Cardiol. 2015 Aug 01; 116(3):492-3.
    View in: PubMed
    Score: 0.127
  109. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS. Hypertrophic Cardiomyopathy in?Adulthood Associated With Low?Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol. 2015 May 12; 65(18):1915-28.
    View in: PubMed
    Score: 0.126
  110. Kalra A, Maron MS, Rowin EJ, Colgan TK, Lesser JR, Maron BJ. Coronary embolization in hypertrophic cardiomyopathy with left ventricular apical aneurysm. Am J Cardiol. 2015 May 01; 115(9):1318-9.
    View in: PubMed
    Score: 0.124
  111. Rowin EJ, Maron BJ, Kiernan MS, Casey SA, Feldman DS, Hryniewicz KM, Chan RH, Harris KM, Udelson JE, DeNofrio D, Roberts WC, Maron MS. Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant. Circ Heart Fail. 2014 Nov; 7(6):967-75.
    View in: PubMed
    Score: 0.121
  112. Rowin EJ, Maron BJ, Lesser JR, Rastegar H, Maron MS. Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management. Am J Cardiol. 2013 Jun 01; 111(11):1677-9.
    View in: PubMed
    Score: 0.109
  113. Rowin EJ, Maron BJ, Maron MS. Reply: To PMID 23245842. Am J Cardiol. 2013 Jan 01; 111(1):150-1.
    View in: PubMed
    Score: 0.107
  114. Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013 Feb 05; 127(5):585-93.
    View in: PubMed
    Score: 0.107
  115. Rowin EJ, Maron BJ, Appelbaum E, Link MS, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron MS. Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. Am J Cardiol. 2012 Oct 01; 110(7):1027-32.
    View in: PubMed
    Score: 0.104
  116. Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson CM, Lesser JR, Lindberg J, Haas TS, Udelson JE, Manning WJ, Maron BJ. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012 Jul; 5(4):441-7.
    View in: PubMed
    Score: 0.103
  117. Bonaventura J, Rowin EJ, Chan RH, Chin MT, Puchnerova V, Polakova E, Macek M, Votypka P, Batorsky R, Perera G, Koethe B, Veselka J, Maron BJ, Maron MS. Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2024 May 21; 13(10):e033565.
    View in: PubMed
    Score: 0.059
  118. Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS, Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Author Correction: Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun. 2024 Apr 08; 15(1):3038.
    View in: PubMed
    Score: 0.059
  119. Narayanan CA, Bokhari N, Rowin EJ, Maron MS, Maron BJ, Link MS, Madias C. Maintenance of Subcutaneous Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy Patients With Iatrogenic Left Bundle-Branch Block After Septal Myectomy. J Am Heart Assoc. 2024 Apr 16; 13(8):e033728.
    View in: PubMed
    Score: 0.059
  120. Bataiosu R, Hoss S, Scolari FL, Cooper C, Tsoi M, Brahmbhatt DH, Billia F, Lee DZJ, Chan R, Ha ACT, Maron BJ, Rowin E, Maron MS, Ralph-Edwards A, Rakowski H, Adler A. Clinical Significance of Postoperative Atrial Fibrillation in Hypertrophic Cardiomyopathy Patients Undergoing Septal Myectomy. Can J Cardiol. 2023 12; 39(12):1931-1937.
    View in: PubMed
    Score: 0.055
  121. Bonaventura J, Maron BJ, Berul CI, Rowin EJ, Maron MS. Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity. Heart Rhythm O2. 2023 Aug; 4(8):506-516.
    View in: PubMed
    Score: 0.055
  122. Wang RS, Rowin EJ, Maron BJ, Maron MS, Maron BA. A novel patient-patient network medicine approach to refine hypertrophic cardiomyopathy subgrouping: implications for risk stratification. Cardiovasc Res. 2023 05 02; 119(3):e125-e127.
    View in: PubMed
    Score: 0.055
  123. Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS, Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Author Correction: Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun. 2022 Nov 17; 13(1):7026.
    View in: PubMed
    Score: 0.053
  124. Abdelfattah OM, Martinez M, Sayed A, ElRefaei M, Abushouk AI, Hassan A, Masri A, Winters SL, Kapadia SR, Maron BJ, Rowin E, Maron MS. Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2022 11; 8(11):1417-1427.
    View in: PubMed
    Score: 0.053
  125. Maron BA, Wang RS, Carnethon MR, Rowin EJ, Loscalzo J, Maron BJ, Maron MS. What Causes Hypertrophic Cardiomyopathy? Am J Cardiol. 2022 09 15; 179:74-82.
    View in: PubMed
    Score: 0.052
  126. Cui H, Schaff HV, Wang S, Lahr BD, Rowin EJ, Rastegar H, Hu S, Eleid MF, Dearani JA, Kimmelstiel C, Maron BJ, Nishimura RA, Ommen SR, Maron MS. Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients?With Obstructive Hypertrophic?Cardiomyopathy. J Am Coll Cardiol. 2022 05 03; 79(17):1647-1655.
    View in: PubMed
    Score: 0.051
  127. Larson A, Codden CJ, Huggins GS, Rastegar H, Chen FY, Maron BJ, Rowin EJ, Maron MS, Chin MT. Altered intercellular communication and extracellular matrix signaling as a potential disease mechanism in human hypertrophic cardiomyopathy. Sci Rep. 2022 03 25; 12(1):5211.
    View in: PubMed
    Score: 0.051
  128. Papanastasiou CA, Zegkos T, Karamitsos TD, Rowin EJ, Maron MS, Parcharidou D, Kokkinidis DG, Karvounis H, Rimoldi O, Maron BJ, Efthimiadis GK. Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. Int J Cardiol. 2021 06 01; 332:127-132.
    View in: PubMed
    Score: 0.048
  129. Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS, Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun. 2021 02 08; 12(1):873.
    View in: PubMed
    Score: 0.047
  130. Habib M, Adler A, Fardfini K, Hoss S, Hanneman K, Rowin EJ, Maron MS, Maron BJ, Rakowski H, Chan RH. Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Cardiac Magnetic Resonance Study. JACC Cardiovasc Imaging. 2021 05; 14(5):947-958.
    View in: PubMed
    Score: 0.046
  131. Kumar KR, Mandleywala SN, Madias C, Weinstock J, Rowin EJ, Maron BJ, Maron MS, Link MS. Single Coil Implantable Cardioverter Defibrillator Leads in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 06 15; 125(12):1896-1900.
    View in: PubMed
    Score: 0.044
  132. Boll G, Rowin EJ, Maron BJ, Wang W, Rastegar H, Maron MS. Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 01 01; 125(1):120-126.
    View in: PubMed
    Score: 0.043
  133. Miller CAS, Maron MS, Estes NAM, Price LL, Rowin EJ, Maron BJ, Link MS. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2019 06 01; 123(11):1859-1862.
    View in: PubMed
    Score: 0.041
  134. Solomon Z, Breton C, Rowin EJ, Maron BJ, Maron MS, Chen FY, Rastegar H. Surgical Approaches to Hypertrophic Obstructive Cardiomyopathy. Semin Thorac Cardiovasc Surg. 2018; 30(2):125-128.
    View in: PubMed
    Score: 0.038
  135. Rastegar H, Boll G, Rowin EJ, Dolan N, Carroll C, Udelson JE, Wang W, Carpino P, Maron BJ, Maron MS, Chen FY. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Ann Cardiothorac Surg. 2017 Jul; 6(4):353-363.
    View in: PubMed
    Score: 0.037
  136. Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, Maron BJ, Maron MS, Maron BA. Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circ Heart Fail. 2017 Apr; 10(4):e003689.
    View in: PubMed
    Score: 0.036
  137. Wang W, Lian Z, Rowin EJ, Maron BJ, Maron MS, Link MS. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017 Mar; 10(3).
    View in: PubMed
    Score: 0.036
  138. Weissler-Snir A, Hindieh W, Gruner C, Fourey D, Appelbaum E, Rowin E, Care M, Lesser JR, Haas TS, Udelson JE, Manning WJ, Olivotto I, Tomberli B, Maron BJ, Maron MS, Crean AM, Rakowski H, Chan RH. Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (?-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2017 Feb; 10(2).
    View in: PubMed
    Score: 0.036
  139. Chan RH, Maron BJ, Olivotto I, Assenza GE, Haas TS, Lesser JR, Gruner C, Crean AM, Rakowski H, Rowin E, Udelson J, Lombardi M, Tomberli B, Spirito P, Formisano F, Marra MP, Biagini E, Autore C, Manning WJ, Appelbaum E, Roberts WC, Basso C, Maron MS. Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Aug 01; 116(3):436-41.
    View in: PubMed
    Score: 0.032
  140. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014 Aug 05; 130(6):484-95.
    View in: PubMed
    Score: 0.030
  141. Gruner C, Chan RH, Crean A, Rakowski H, Rowin EJ, Care M, Deva D, Williams L, Appelbaum E, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Siminovitch K, Ralph-Edwards AC, Rastegar H, Maron BJ, Maron MS. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Eur Heart J. 2014 Oct 14; 35(39):2706-13.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.